Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TEVA 
Teva Pharma Industries Ltd ADR (TEVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: TEVA (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $23.56
1 Year Target Price $23.56
| 6 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 28.84% | Avg. Invested days 60 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 22.73B USD | Price to earnings Ratio - | 1Y Target Price 23.56 |
Price to earnings Ratio - | 1Y Target Price 23.56 | ||
Volume (30-day avg) 11 | Beta 0.72 | 52 Weeks Range 12.47 - 22.80 | Updated Date 09/16/2025 |
52 Weeks Range 12.47 - 22.80 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.94% | Operating Margin (TTM) 21.41% |
Management Effectiveness
Return on Assets (TTM) 5.37% | Return on Equity (TTM) -2.42% |
Valuation
Trailing PE - | Forward PE 7.02 | Enterprise Value 38086471328 | Price to Sales(TTM) 1.37 |
Enterprise Value 38086471328 | Price to Sales(TTM) 1.37 | ||
Enterprise Value to Revenue 2.29 | Enterprise Value to EBITDA 20.06 | Shares Outstanding 1147149952 | Shares Floating 1141529878 |
Shares Outstanding 1147149952 | Shares Floating 1141529878 | ||
Percent Insiders - | Percent Institutions 65.03 |
Upturn AI SWOT
Teva Pharma Industries Ltd ADR
Company Overview
History and Background
Teva Pharmaceutical Industries Ltd. was founded in 1901. It has grown through acquisitions and strategic partnerships to become a leading global pharmaceutical company, specializing in generic and specialty medicines.
Core Business Areas
- Generics: Teva's generics business develops, manufactures, and markets a wide range of generic medicines in various dosage forms and therapeutic areas.
- Specialty Medicines: Teva's specialty medicines business focuses on treatments for central nervous system (CNS) disorders, pain, and respiratory diseases.
- Biopharmaceuticals: Teva develops and manufactures biosimilars.
Leadership and Structure
Teva is led by a global management team. The company operates with a structure that supports its generic, specialty, and biopharmaceutical businesses.
Top Products and Market Share
Key Offerings
- Copaxone: A treatment for multiple sclerosis. While it was once a major revenue driver, its market share has significantly declined due to generic competition. Competitors include Biogen and Novartis.
- Austedo: A treatment for Huntington's disease and tardive dyskinesia. Competitors include Ingrezza and Xenazine.
- Ajovy: A calcitonin gene-related peptide (CGRP) inhibitor for the preventive treatment of migraine. Competitors include Amgen, Eli Lilly, and Novartis.
- Generic Products: A wide array of generic pharmaceuticals, addressing various therapeutic needs and competing with generic products from Mylan, Viatris, Sandoz and others.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, regulatory scrutiny, and the constant need for innovation. The generic drug market is particularly competitive, facing price erosion and increasing demand for biosimilars.
Positioning
Teva is a leading generic pharmaceutical company with a presence in specialty medicines. The company faces challenges related to debt, generic price erosion, and competition from other players.
Total Addressable Market (TAM)
The global pharmaceuticals market is valued in the trillions of USD. Teva is positioned to capture a portion of this market, focusing on generic drugs, specialty medicines, and biosimilars. The TAM for generics is particularly large.
Upturn SWOT Analysis
Strengths
- Extensive global distribution network
- Broad portfolio of generic medicines
- Established presence in specialty medicines
- Experience in biopharmaceutical development
Weaknesses
- High debt levels
- Exposure to generic price erosion
- Past legal issues
- Dependence on key products with expiring patents
Opportunities
- Expanding biosimilar market
- Growing demand for affordable medicines
- Strategic partnerships and collaborations
- Emerging markets growth
Threats
- Intense competition in the generic market
- Regulatory changes and pricing pressures
- Patent expirations
- Economic downturns
Competitors and Market Share
Key Competitors
- VTRS
- MYL
- SNY
Competitive Landscape
Teva faces intense competition in the generic pharmaceutical market. Its competitive advantages include its global presence and broad product portfolio. However, its high debt levels and exposure to generic price erosion are disadvantages.
Major Acquisitions
Actavis Generics
- Year: 2016
- Acquisition Price (USD millions): 40500
- Strategic Rationale: This acquisition significantly expanded Teva's generic portfolio and global footprint.
Growth Trajectory and Initiatives
Historical Growth: Teva's historical growth has been driven by acquisitions and generic drug launches. However, the company has faced challenges due to increased competition and pricing pressures.
Future Projections: Future growth is expected to come from new product launches, biosimilar development, and cost-cutting measures. Analyst estimates vary depending on Teva's ability to execute its strategy.
Recent Initiatives: Recent initiatives include debt reduction, restructuring, and a focus on innovative medicines and biosimilars.
Summary
Teva is a leading generic pharmaceutical company navigating a challenging market. While it has a strong global presence and broad product portfolio, its high debt and generic pricing pressure pose significant hurdles. The company is focusing on debt reduction, restructuring, and new product launches to improve its financial performance and future growth. Teva needs to focus on reducing debt and driving future growth in biosimilars to improve its situation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data can vary depending on the source. Financial data is based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Teva Pharma Industries Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 1990-03-26 | President, CEO & Director Mr. Richard D. Francis | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 37000 | Website https://www.tevapharm.com |
Full time employees 37000 | Website https://www.tevapharm.com | ||
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.